C-DQNFBloom Science
live biotherapeutics, gut-brain axis, ketogenic biology
Loading
Loading section...0-100 chain-logic scale · 15 dimensions · scored on public evidence
C-DQNFlive biotherapeutics, gut-brain axis, ketogenic biology
0-100 chain-logic scale · 15 dimensions · scored on public evidence
Bloom Science states that it is developing a new generation of live biotherapeutic medicines for neurological diseases and conditions by starting with the gut microbiome, with a focus on underserved patients with rare or complex conditions who have not responded to existing therapies. The company presents the gut-immune-brain axis as the core basis for its therapeutic approach.
SourceNo company beliefs, mission, or longevity-related positions are stated in this snapshot; it is a domain-sale landing page for BloomScience.com.
SourceBloom Science states that interactions between gut bacteria and the human host are as critical as genetics and are a driving factor in many diseases with poorly understood causes. The company presents the gut-immune-brain axis as a tractable therapeutic target and argues that rationally engineered microbiota-based living medicines, reverse engineered from positive clinical outcomes and built from well-studied gut microbes, can safely and effectively address drug-resistant or otherwise underserved diseases.
SourceBloom Science states that interactions between gut bacteria and the human host are as critical as genetics and are a driving factor in many diseases with poorly understood causes. The company says it is leveraging the gut-immune-brain axis and applying rational drug discovery principles to engineer microbiota-based drug candidates, positioning this as a fundamentally different path to therapeutic solutions for patients.
SourceThe snapshot does not contain any stated beliefs, mission, or scientific/longevity position from Bloom Science. It only shows a parked domain sales page from Undeveloped indicating that BloomScience.com was for sale.
Source